184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)
暂无分享，去创建一个
E. Zecca | G. Viscardi | G. Galli | R. Ferrara | A. Prelaj | C. Proto | A. Labianca | M. Brambilla | M. Ganzinelli | M. Occhipinti | D. Signorelli | G. Russo | A. D. Toma | E. Zattarin | F. Braud | T. Beninato | M. Bini | M. Garassino | S. Manglaviti